Objectives To evaluate the surgical staging with systematic pelvic lymphadenectomy in patients with endometrial adenocarcinoma submitted to sentinel lymph node screening with patent blue injection.

Methods A retrospective study of medical records from patients submitted to screening and sentinel lymph node with the patent blue attended in cancer service linked to the Oncoclínicas Group of Brazil, by the Unified Health System (SUS) from January 2015 to May 2017. The inclusion criteria were patients with endometrial biopsy with histological endometrioid adenocarcinoma with computed tomography image revealing the disease restricted to the uterus, stage Ia-Ib2 and histological grades I-II.

Results The sample consisted of 15 patients with a mean age of 56.07 ± 11.55 years. The clinical staging was IB for 93.3% of the patients, and the surgical staging was IB for 66.7% of the patients. In the evaluation of the evolution of clinical and surgical staging, 73.3% maintained staging and 26.7% confirmed more advanced staging by paraffin. The histological grades obtained by the biopsy and the surgical specimen were not associated. Two patients that the lymph nodes captured the patent blue had the disease confirmed by the pathological anatomy. There was a significant association between these characteristics (p=0.029).

Conclusions despite the small sample size, we observed that the sentinel lymph node biopsy would be enough to direct the lymphadenectomy and define the surgical staging in 90% of the patients evaluated.